|
Oct 8
|
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
|
|
Jun 24
|
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
|
|
Jun 17
|
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
|
|
May 13
|
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
Apr 2
|
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
|
|
Mar 29
|
Avalo Reports 2023 Financial Results and Provides Business Updates
|
|
Mar 27
|
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
|
|
Dec 27
|
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
|
|
Dec 7
|
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
|
|
Sep 26
|
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
|